Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Open-Label Study Evaluating Sustained Virological Response and Safety With Boceprevir in Triple Combination Therapy With Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-Naïve Patients With Genotype 1 Chronic Hepatitis C

NCT01591460 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01591460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01591460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Open-Label Study Evaluating Sustained Virological Response and Safety With Boceprevir in Triple Combination Therapy With Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-Naïve Patients With Genotype 1 Chronic Hepatitis C
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2012
Completion date
June 30, 2014
Enrollment
165 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic